Cyclopropanes

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

Tuesday, January 12, 2021 - 3:37am

TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

Monday, January 4, 2021 - 12:00pm

As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population.

Key Points: 
  • As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population.
  • The primary study endpoint is PFS by blinded independent review.
  • Median PFS was 9.2 months among patients treated with telaglenastat and cabozantinib as compared to 9.3 months with cabozantinib and placebo.
  • Calithera is conducting the randomized Phase 2 KEAPSAKE trial to evaluate telaglenastat in patients with advanced non-small cell lung cancer harboring KEAP1/NRF2 mutations.

Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial

Friday, December 11, 2020 - 10:00pm

The razuprotafib once-daily (QD) dose group did not show a statistically significant improvement at Day 28.

Key Points: 
  • The razuprotafib once-daily (QD) dose group did not show a statistically significant improvement at Day 28.
  • The study was designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib as an adjunct to standard of care latanoprost.
  • The primary endpoint of the study was mean diurnal IOP at 28 days in the razuprotafib treated groups compared to the latanoprost monotherapy group.
  • Aerpio is studying a topical ocular formulation of razuprotafib in open angle glaucoma and exploring the utility of subcutaneous razuprotafib for diabetic complications, including diabetic nephropathy.

Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Monday, November 30, 2020 - 2:15pm

The NDA submission includes data from the SURE-1, SURE-2 and SURE-3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no significant drug related adverse events.

Key Points: 
  • The NDA submission includes data from the SURE-1, SURE-2 and SURE-3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no significant drug related adverse events.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Salix's Methylnaltrexone Abstract Wins Best Of Meeting Award At ASRA's Annual Pain Medicine Meeting

Thursday, November 19, 2020 - 2:04pm

"Salix is honored to be recognized by ASRA for a Best of Meeting Award, a distinction that is reserved for the highest scoring scientific abstracts.

Key Points: 
  • "Salix is honored to be recognized by ASRA for a Best of Meeting Award, a distinction that is reserved for the highest scoring scientific abstracts.
  • Our scientific poster presentation includes analyses examining the effects of subcutaneous methylnaltrexone in cancer and non-cancer patients with opioid-induced constipation,"said Howard Franklin, M.D., chief medical officer, Salix.
  • The Salix abstract will be available via the ASRA online portal beginning Nov. 21:
    Shah, Eric.
  • Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care.

QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours

Wednesday, November 18, 2020 - 12:10pm

The efficacy and durability of response data in dogs with mast cell tumours are very promising.

Key Points: 
  • The efficacy and durability of response data in dogs with mast cell tumours are very promising.
  • While surgery will remain the mainstay, I do think STELFONTA will reshape how we approach local mast cell tumour control in many ways."
  • Dr Victoria Gordon, CEO and Managing Director of QBiotics, said, "FDA approval is a pivotal achievement for both STELFONTA and QBiotics.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoural treatment of canine mast cell tumours with tigilanol tiglate (EBC-46).

QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours

Wednesday, November 18, 2020 - 12:10pm

The efficacy and durability of response data in dogs with mast cell tumours are very promising.

Key Points: 
  • The efficacy and durability of response data in dogs with mast cell tumours are very promising.
  • While surgery will remain the mainstay, I do think STELFONTA will reshape how we approach local mast cell tumour control in many ways."
  • Dr Victoria Gordon, CEO and Managing Director of QBiotics, said, "FDA approval is a pivotal achievement for both STELFONTA and QBiotics.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoural treatment of canine mast cell tumours with tigilanol tiglate (EBC-46).

BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study

Monday, November 16, 2020 - 1:30pm

Lourdes vital contribution to the Company makes her the right CEO for the next chapter at BioCorRx.

Key Points: 
  • Lourdes vital contribution to the Company makes her the right CEO for the next chapter at BioCorRx.
  • In our partnership over the years, she has been a key player in defining and executing on our strategic initiatives, said Mr. Granier.
  • I am grateful and honored to serve as CEO of BioCorRx and appreciate the confidence shown by Brady and the Board of Directors, said Lourdes.
  • Our subsidiary, BioCorRx Pharmaceuticals Inc., continues to progress our pivotal good laboratory practice (GLP) preclinical studies of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.

IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

Monday, November 9, 2020 - 1:30pm

We are very encouraged that the current study, which includes additional prescription database data and results from the Troms Study, further supports Montelukasts potential to postpone mental aging.

Key Points: 
  • We are very encouraged that the current study, which includes additional prescription database data and results from the Troms Study, further supports Montelukasts potential to postpone mental aging.
  • The article, co-authored by Dr. Aigner from the Paracelsus Medical University in Salzburg, Austria, is entitled, A possible effect of montelukast on neurological aging examined by the use of register data.
  • The study used multivariate linear regression analyses to see how the use of various medications was associated with neurological health test results.
  • The study found that previous use of Montelukast correlated with improved scores on cognitive or neurological functioning, suggesting that Montelukast may alleviate degenerative neurological changes associated with human aging.

BRILINTA Approved in the US to Reduce the Risk of Stroke in Patients With an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Friday, November 6, 2020 - 12:00pm

BRILINTA is a well-established medicine across patients with coronary artery disease and with todays approval, we can now expand its potential to patients with an acute ischemic stroke or transient ischemic attack.

Key Points: 
  • BRILINTA is a well-established medicine across patients with coronary artery disease and with todays approval, we can now expand its potential to patients with an acute ischemic stroke or transient ischemic attack.
  • The risk for severe bleeding events was 0.5% in patients receiving aspirin plus BRILINTA and 0.1% for aspirin alone.
  • BRILINTA is indicated to reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
  • Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services.